Company: RCUS
Filing Date: 2025-08-06
Form Type: 10-Q
Source: 0001724521-25-000101
Chunk: 223

Company: Arcus Biosciences, Inc.
Filing Date: 2025-08-06
Form: 10-Q
Item: Part I, Item 1
Chunk 223
---
ilead’s option under the Gilead Collaboration Agreement and Gilead has no further rights to the program. 

21

The following chart summarizes our current clinical pipeline:

cabo: cabozantinib; cas: casdatifan; chemo: chemotherapy; dom: domvanalimab; etruma: etrumadenant; gem/nab-pac: gemcitabine/nab-paclitaxel; IO: immuno-oncology; ipi: ipilimumab nivo: nivolumab; pembro: pembrolizumab; quemli: quemliclustat; rego: regorafenib; volru: volrustomig; zanza: zanzalintinib; zim: zimberelimab.

* Gilead and Arcus co-develop globally and share co-commercialization rights in the U.S. for domvanalimab, zimberelimab and quemliclustat. Gilead holds commercialization rights outside of the U.S. subject to any third-party rights.

**+/- biologic, e.g. bevacizumab or biosimilar, will be included for all patients in whom it is not contraindicated.

22

Significant Developments

The following is a summary of the recent significant developments affecting our business:

HIF-2α Program (casdatifan)

•In June 2025, we presented initial data from the ARC-20 study evaluating casdatifan plus cabozantinib that showed that nearly half of patients with metastatic cancer had a confirmed response:

◦Treatment with casdatifan, a HIF-2a inhibitor, plus cabozantinib, a tyrosine kinase inhibitor, showed a confirmed overall response rate of 46% in patients who reached a minimum of 12 weeks (two scans) of follow-up,

◦The combination had a manageable safety profile, and there was no meaningful overlapping toxicity for the two drugs.

•The data supported the initiation of two studies:

◦PEAK-1, a Phase 3 study evaluating casdatifan plus cabozantinib versus cabozantinib in immunotherapy-experienced clear cell renal cell carcinoma ("ccRCC"), that has been initiated; and

◦eVOLVE-RCC02, a Phase 1b/3 study sponsored and operationalized by AstraZeneca, evaluating casdatifan plus vol